Insmed, Inc. announced ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients.
ARIKAYCE can be used for patients with MAC lung disease, a chronic and debilitating condition that can significantly increase patient morbidity and mortality.
It is being assessed as a treatment for lung infections caused by Non-Tuberculosis Mycobacteria (NTM) in patients with Cystic Fibrosis (CF) as well as other lung diseases.
Amikacin is currently approved for intravenous or intramuscular use to treat serious bacterial infections.
ARIKAYCE provides a much-needed treatment for patients with this chronic and life-threatening disease who have not responded to the current standard of care.
It has the potential to address the significant unmet needs in this difficult-to-treat population.
The company is committed to providing access to ARIKAYCE for appropriate patients with MAC lung disease and to supporting these patients throughout their treatment journey.
Patients who are prescribed ARIKAYCE will be provided with a Medication Guide containing important safety information set forth below, including the boxed warning, as well as full Instructions for Use and a step-by-step guide to using the product.
Insmed reports that the liposomal packaging of amikacin allows it to be delivered to the macrophages at high concentrations.
In other words, the particle nature of the liposomes could be the key to its effectiveness.
ARIKAYCE is administered once daily using the Lamira™ Nebulizer System.
